Sobi, a leading integrated global biopharmaceutical company dedicated to rare and difficult-to-treat diseases, announced today that Trista Morrison, an experienced corporate communications leader and former journalist, has joined the company as vice president of communications for North America.
Morrison will support Sobi’s growth in the region by building the communications function in North America and strengthening Sobi’s connection with patients, caregivers, healthcare professionals, advocacy groups and potential partners. She will also collaborate closely with the Sobi global communications team on integrated, worldwide communications initiatives.
Morrison’s more than 15 years in biopharmaceutical communications span corporate, reporter and agency roles. Most recently, Morrison served as director of corporate communications for Ironwood Pharmaceuticals, where she led internal, external and brand communications as the company transitioned from a research and development organization to a fully integrated commercial biotechnology company. Prior to her role at Ironwood, Morrison served as an editor and staff writer at BioWorld Today, covering breaking news and trends in the biopharmaceutical industry. Previously she served in various positions with biopharmaceutical-focused public relations agency Porter Novelli Life Sciences (formerly Atkins + Associates). Morrison was honored as one of PR News’ Top Women in PR in 2017, which recognizes communicators who have made bold advances in the profession.
“Sobi is a pioneer in rare and difficult-to-treat diseases, striving to create a world where patients with these conditions are diagnosed at birth and receive the care they need throughout their lives,” said Rami Levin, president of Sobi in North America. “This is an ambitious goal that requires communication and partnership between multiple stakeholders, and we look forward to working with Trista to advance this important work in North America.”
“The Sobi team is incredibly passionate about the work we do and dedicated to the patients and communities we serve. I am proud to be a part of this team and look forward to increasing our communication with key stakeholders as our business continues to grow,” said Morrison.
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.